DALLAS (WBAP/KLIF)- Covid-19 patients in DFW will be the first to participate in a series of nation-wide phase 2 clinical studies to treat gut infections caused by the virus. Biopharmaceutical company AzurRx is seeking to enroll patients for a drug to treat gastrointestinal (GI) infection symptoms associated with COVID-19, including severe diarrhea, vomiting and abdominal…… MORE
